Skip to main content
Medicine logoLink to Medicine
. 2023 Feb 17;102(7):e33038. doi: 10.1097/MD.0000000000033038

Frontier and hotspot evolution in Brugada syndrome: A bibliometric analysis from 2002 to 2022

Shixu Liu a, Hongsheng Xia a, Xiaoyan Yao a, Hengyuan Liu b, Yanyi Liu a, Xiao Xia a, Dandan Wang a, Xiaohong Liu a, Guangxi Li a,*
PMCID: PMC9935997  PMID: 36800577

Background:

Brugada syndrome (BrS) is a genetic disorder characterized by a typical electrocardiogram pattern and predisposition to arrhythmias and sudden cardiac death. Despite our considerably evolved understanding of BrS, no bibliometrics have been performed in this research field. We aimed to analyze and visualize the characteristics of the scientific outputs, topical evolutions, and research trends of BrS over the past 2 decades using bibliometric analysis.

Methods:

The literature associated with BrS was retrieved from the Science Citation Index Expanded of the Web of Science Core Collection database. Acquired data were then visually analyzed using CiteSpace and VOSviewer.

Results:

3042 qualifying records were included in the final analysis. The publication outputs increased over time. The United States was the leading country in the BrS research. The University of Amsterdam (Netherlands) was the most prolific and influential institution. Pedro Brugada, Arthur Wilde, and Charles Antzelevitch exerted notable publication impact and made the most significant contributions in the field of BrS. Heart Rhythm had the highest outputs and Circulation was the most influential journal. Bundle branch block, ST-segment elevation, mechanism, management, right precordial lead, and guideline were the keywords with the strongest citation burst.

Conclusion:

Research on BrS is prosperous. Keywords and co-citation analysis revealed that the mechanism, diagnosis, risk stratification, and management of BrS were the research hotspots. Besides, the underlying pathophysiology, novel therapies, and personalized risk assessment might be the emerging trends of future research.

Keywords: arrhythmia, bibliometric analysis, Brugada syndrome, CiteSpace, sudden cardiac death, VOSviewer

1. Introduction

In 1992, the Brugada brothers reported that 8 individuals suffered from sudden cardiac death (SCD) caused by documented ventricular fibrillation (VF). These patients had characteristic electrocardiogram (ECG) changes of ST-segment elevation in the right precordial leads in a structurally normal heart.[1] This disease was initially known as “right bundle branch block, persistent ST-segment elevation, and sudden death syndrome” until 1996, when the new clinical entity was named Brugada syndrome (BrS) for the first time.[2,3] In 1997, BrS and sudden unexplained nocturnal death syndrome were recognized as the same disorder.[4] BrS and other primary electrical diseases have common denominator alterations of ionic currents resulting in depolarization and repolarization abnormalities.[5]

BrS typically manifests in the third or fourth decade of life.[6] Most individuals with a Brugada ECG are asymptomatic. A small minority develop ventricular arrhythmias (VAs) that result in trouble breathing, syncope, and even SCD.[6] The familial nature of BrS soon became evident, supporting an autosomal dominant pattern of inheritance.[7] To date, more than 300 mutations associated with BrS have been reported in 19 different genes, which encode sodium, potassium, and calcium channels or associated proteins.[5] In 1998, the first genetic alteration was identified in the SCN5A gene, which encodes for the α-subunit of the NaV1.5 sodium channel.[8] It is difficult to discern the true burden of BrS owing to the unknown prevalence of asymptomatic patients. Nonetheless, the prevalence of BrS is estimated to affect 1 in 2000 worldwide.[9] This condition is more common in males than females and those of Asian descent.[9]

The diagnosis of BrS is a clinical-electrocardiographic one.[5] Three forms of the BrS ECG pattern have historically been described, although only type 1 is considered diagnostic, which consists of coved ST-segment elevation ≥ 2 mm with T-wave inversion in the right precordial leads.[10] No cure for BrS exists, so far. Lifestyle changes are advised including prompt treatment for fever and avoidance of contraindicated substances.[11] An implantable cardioverter defibrillator (ICD) should always be implanted in symptomatic patients, with quinidine and ablation used for patients with recurrent arrhythmia.[9] Notwithstanding progressive understanding of this clinical entity over the last 30 years, comprehensive reports that can benefit scholars to obtain an intuitive overview and reveal research trends are still absent.

Bibliometric analysis is a statistical approach to exploring and analyzing large volumes of scientific data.[12] Combining visualizing processing tools like CiteSpace[13] and VOSviewer,[14] it utilizes published data to identify novel findings and current research trends of a particular topic. Therefore, clinical practitioners and researchers can update the new practices that evoke novel research ideas, providing the foundation for the subsequent studies.[15,16] Over the years, bibliometric analysis has been employed in many health topics, including rare diseases.[17,18] Given the extensive study of BrS, a bibliometric analysis is war-ranted to acknowledge and celebrate those contributing to this important part of channelopathies research. This study aimed at exploring hotspot evolution and frontier of the BrS field by analyzing scientific literature from 2002 to 2022, to provide new visions for future researchers and clinical workers, especially for those who have curiosity but are novices in this field.

2. Materials and methods

2.1. Data collection

All scientific literature was retrieved from the Science Citation Index Expanded of the Web of Science Core Collection database. According to the MeSH term, we used “ Topic Search = Brugada syndrome” as the search strategy, and the search period was limited from 2002.01.01 to 2022.06.23. Only articles and review articles written in English were included. Record content selected full record and cited references. The records were exported as plain text files and saved in the format of download.txt. The entire process was conducted within 1 day (June 23, 2022) to reduce the bias associated with database updating.

2.2. Data analysis

The number of publications (Np) and citations without self-citations (Nc) are 2 main bibliometric indicators for judging academic success. In general, Np is used to measure productivity, and Nc is the yardstick of scientific impact. The h-index is a research-level metric that evaluates both the productivity and citation impact of the publications by finding the threshold that connects Np with Nc. It is defined as the maximum value of h so that the given scholar has published at least h papers that have each been cited no less than h times.[19] The index has more recently been applied to the productivity and impact of a journal as well as an institution or a country.[20] Besides, the impact factor obtained from the latest 2021 Journal Citation Reports can be used as a proxy for the relative importance of a journal within its field.[21]

Relevant data were imported into CiteSpace and VOSviewer to perform visual analysis. CiteSpace version 6.1.R2 (Drexel University, Philadelphia, PA) was applied to analyze the contribution and cooperative relationship analysis. Developed by Chen,[22] Citespace is a tool for progressive knowledge domain visualization. It is particularly applicable for analyzing and visualizing patterns and trends in scientific literature. The main objective of knowledge domain visualization is to find key points in the development of research. CiteSpace provides a visual aid that characterizes the research hotspots and evolution processes, as well as forecasts the future trends of the domain intuitively.[13,23] VOSviewer version 1.6.18 (Leiden University, Leiden, Netherlands) was used to illustrate the keyword co-occurrence analysis. Unlike the conventional tools for constructing and viewing bibliometric networks, VOSviewer focuses on the graphic representation of knowledge mappings. It is ideal for sizable bibliometrics display in an easy-to-explain way.[14] Scimago Graphica was also involved for a more precise presentation of the analysis.

3. Quantitative analysis of basic information

3.1. Analysis of publications distribution

As shown in Figure 1, the publication outputs and citations concerning BrS demonstrated an overall upward trend. From 2002 to 2022, 3042 BrS-themed publications (including 2464 articles and 578 review articles) were issued on Web of Science Core Collection. The total citations without self-citations were 58,440, and the average number of citations was 30.93 per item. The h-index of all papers was 133. 2018 and 2021 were the 2 most productive years with 208 and 206 published papers, respectively.

Figure 1.

Figure 1.

Trends of BrS-themed publications over the past 20 years. BrS = Brugada syndrome.

Five hundred and thirty-seven academic journals were involved in the BrS research. The top 10 productive journals are listed in Table 1. Five journals had more than 100 papers, and Heart Rhythm ranked first (Np = 227, Nc = 9151, h-index = 55). Although Circulation preserved 90 publications, it had the highest citations, h-index, and impact factor (Nc = 15,510, h-index = 66, impact factor = 39.918). Journals of the American College of Cardiology had the second high impact factor (27.203). The number of times that a journal is co-cited, is an important scientific metric to measure whether it has a considerable impact in the domain. Five journals had been co-cited more than 5000 times. Again, Circulation, Journals of the American College of Cardiology, and Heart Rhythm were the top 3 in co-citations. Nearly all the top 10 journals and co-cited journals belong to Q1 or Q2, based on the latest Journal Citation Reports in 2021.

Table 1.

Top 10 journals and co-cited journals related to BrS (2002–2022).

No Journal Np h-index Nc IF JCR Journal Nc IF JCR
1 Heart Rhythm 227 55 9151 6.779 Q1 Circulation 1,8409 39.918 Q1
2 Europace 139 28 2464 5.486 Q2 JACC 9529 27.203 Q1
3 JCE 132 33 3391 Heart Rhythm 8200 6.779 Q1
4 J Electrocardiol 129 18 1633 1.38 Q4 JCE 5547
5 PACE 114 22 1785 1.976 Q3 Circ Res 5068 23.213 Q1
6 Circulation 90 66 15,510 39.918 Q1 Eur Heart J 3726 35.855 Q1
7 ANE 86 17 964 1.485 Q4 Cardiovasc Res 2895 13.081 Q1
8 Circ J 82 24 1608 3.35 Q3 Circ Arrhythm Electrophysiol 2715 6.568 Q1
9 Circ Arrhythm Electrophysiol 78 33 3431 6.568 Q1 NEJM 2593 176.079 Q1
10 JACC 74 19 1598 27.203 Q1 Europace 2413 5.486 Q2

ANE = Annals of Noninvasive Electrocardiology, BrS = Brugada syndrome, IF = impact factor, JACC = Journal of the American College of Cardiology, JCE = Journal of Cardiovascular Electrophysiology, JCR = Journal Citation Reports, Nc = citations without self-citations, NEJM = New England Journal of Medicine, PACE = Pacing and Clinical Electrophysiology.

3.2. Analysis of contribution and cooperative relationship

During 2002 to 2022, 82 countries, 2689 institutions, and 10,952 authors were involved in the BrS research. The top 10 high-output countries and their cooperation are presented in Figure 2. As shown in Table 2, the USA employed the highest number of papers (Np = 910, 29.91%), far above second-ranked Japan (Np = 512, 16.83%) and third-ranked Italy (Np = 340, 11.18%). The USA also received the highest citations (Nc = 38,817) and h-index (110). Notably, the Netherlands had the second-best metrics (Nc = 16,618, h-index = 75) with only 288 papers.

Figure 2.

Figure 2.

Country collaboration network (A) and top 10 countries (B) in BrS research (2002–2022). BrS = Brugada syndrome.

Table 2.

Top 10 countries/regions for publications and centrality in the field of BrS (2002–2022).

Rank Country/region Np (% of 3042) Nc h-index Country/region BC
1 USA 910 (29.91%) 38,817 110 USA 0.28
2 Japan 512 (16.83%) 15,035 62 United Kingdom 0.2
3 Italy 340 (11.18%) 14,376 62 Spain 0.2
4 Netherlands 288 (9.47%) 16,618 75 France 0.16
5 France 254 (8.35%) 13,278 59 Germany 0.15
6 United Kingdom 253 (8.32%) 7661 46 Italy 0.13
7 China 250 (8.22%) 3931 33 Canada 0.13
8 Germany 233 (7.66%) 13,774 56 Denmark 0.12
9 Spain 211 (6.94%) 9566 48 South Africa 0.11
10 Canada 209 (6.87%) 6732 43 Switzerland 0.1

BC = betweenness centrality, BrS = Brugada syndrome, Nc = citations without self-citations, Np = number of publications.

The top 10 productive institutions and institutional cooperation are demonstrated in Figure 3B. As depicted in Table 3, the University of Amsterdam had the highest outputs, citations, and h-index (Np = 183, Nc = 14,440, h-index = 70), followed by Masonic Medical Research Institute (Np = 119, Nc = 11,304, h-index = 54). Betweenness centrality (BC) measures the strength of the connection between a node and other nodes.[24] CHU de Nantes and the University of Pavia had a high BC (>0.1), as indicated by the node’s purple trims in Figure 3A. Such nodes tend to have more influence and bridge different entities within the domain.

Figure 3.

Figure 3.

Institution collaboration network (A) and top 10 Institutions (B) in BrS research (2002–2022). BrS = Brugada syndrome.

Table 3.

Top 10 institutions for publications and betweenness centrality in the field of BrS (2002–2022).

No. Institutions Country Np Nc h-index Institutions BC
1 Univ Amsterdam Netherlands 183 14,440 70 CHU Nantes 0.17
2 MMRI USA 119 11,304 54 Univ Pavia 0.13
3 Mayo Clin USA 86 6108 45 Univ Amsterdam 0.1
4 Univ Barcelona Spain 78 7276 40 MMRI 0.1
5 NCVC Japan 65 5775 37 NYU 0.09
6 SGUL England 62 2436 27 Univ Barcelona 0.08
7 Univ Pavia Italy 60 6101 39 Lankenau Med Ctr 0.07
8 Okayama Univ Japan 59 2976 30 Mayo Clin 0.06
9 CHU Nantes France 59 8679 41 Vanderbilt Univ 0.06
9 Vanderbilt Univ USA 56 4811 34 INSERM 0.06

BC = betweenness centrality, BrS = Brugada syndrome, INSERM = French National Institute of Health and Medical Research (French: Institut national de la santé et de la recherche médicale), MMRI = Masonic Medical Research Institute, Nc = citations without self-citations, NCVC = National Cerebral and Cardiovascular Center, Np = number of publications, NYU = New York University, SGUL = St George’s, University of London.

The top 10 prolific authors and their collaboration network are illustrated in Figure 4B. Table 4 also lists the top 10 highly cited authors and co-cited authors. Pedro Bugada had the highest number of published papers (Np = 135). Besides, Author Wilde, Charles Antzelevitch, Ramon Brugada, and Joseph Brugada published more than 100 papers. As for the citations and h-index, Author Wilde (Nc = 5635, h-index = 56) and Charles Antzelevitch (Nc = 5477, h-index = 55) were much higher than other scholars. There were some obvious collaboration networks as shown in Figure 4A, such as the Brugadas, Charles Antzelevitch and Wataru Schimizu, Author Wilde, Frederic Sacher and Connie Bezzina. Those authors also had relatively high BC, which implies that they had more impact on others’ work and studies from other groups. Two authors are considered as being co-cited when one or more papers from each author’s oeuvre occur in the same reference list.[25] Five authors had a co-citation frequency of more than 1000 times. Charles Antzelevitch (3025) was the most frequently co-cited author, followed by Silvia Priori (2754).

Figure 4.

Figure 4.

Author collaboration network (A) and top 10 authors (B) in BrS research (2002–2022). BrS = Brugada syndrome.

Table 4.

Top 10 authors, cited authors, and co-cited authors of BrS (2002–2022).

No. Author Np h-index BC Cited author Nc Co-cited author Nc
1 Brugada P 135 40 0.06 Wilde AAM 5635 Antzelevitch C 3025
2 Wilde AAM 131 56 0.05 Antzelevitch C 5477 Priori SG 2754
3 Antzelevitch C 128 55 0.04 Ackerman MJ 4232 Brugada P 1592
3 Brugada R 109 40 0.02 Borggrefe M 2847 Brugada J 1100
3 Brugada J 101 40 0.03 Brugada P 2782 Schwartz PJ 1046
6 Ackerman MJ 79 45 0.03 Brugada R 2614 Wilde AAM 929
6 Sacher F 79 30 0.06 Brugada J 2594 Yan GX 841
8 Probst V 78 35 0.01 Probst V 2514 Shimizu W 795
8 Shimizu W 76 35 0.06 Tan HL 2478 Probst V 715
10 Bezzina CR 69 37 0.02 Shimizu W 2468 Morita H 698

BC = betweenness centrality, BrS = Brugada syndrome, Nc = citations without self-citations, Np = number of publications.

4. Analysis of hotspots and frontiers

4.1. Keyword analysis

Keyword analysis can effectively track research hotspots and predict developmental trends.[22] There were 6186 keywords in 3042 papers, among which 16 keywords appeared more than 200 times, and 45 keywords occurred 100 times or above. Figure 5 shows the keyword co-occurrence, clustering, density distribution (Fig. 5C), and top 20 keywords (Fig. 5D). As shown in Figure 5A, Brugada syndrome (2308), ST-segment elevation (986), sudden cardiac death (784), and long QT syndrome (674) were keywords with the biggest nodes, highest density, and frequency, which are consistent with the theme of our study. As for the other keywords, some are signs and symptoms like arrhythmia (556) and VF (539). Some are associated with mechanisms and pathophysiology of BrS, such as mutation (445), SCN5A (306), genetics (238), cellular basis (178). Bundle branch block (652) and electrocardiogram (229) belong to medical diagnosis. Besides, risk stratification (362) is critical in previous management. Descriptive terms such as sudden death, death, prevalence, and risk, correspond to scholars’ concerns about different aspects of BrS, which reflect the severity and complexity of this disease more or less.

Figure 5.

Figure 5.

Keyword co-occurrence (A), clustering (B), keyword density map (C), and top 20 keywords (D) in the field of BrS (2002–2022). BrS = Brugada syndrome.

Keyword clustering is combining similar, relevant queries into groups and using whole groups instead of separate keywords, which helps reflect knowledge core structure. Co-occuring keywords concerning BrS can be divided into 10 main clusters (Fig. 5B). Most clusters were associated with disease’s causes or genetics, including #3 genome wide association, #4 NaV1.5 channel, #5 deletion, #6 sodium channel, and #8 potassium channel. #0 long qt syndrome, #2 torsade de pointe, and #7 idiopathic VF correlated to signs and symptoms of BrS. #1 risk stratification and #9 ecg were management modalities and diagnosis methods for BrS, respectively.

Keywords with the strongest citation bursts appear frequently over a period of time and can reflect the research hotspots and their evolution in the corresponding duration. Table 5 sorts out the burst keywords within the BrS field from 2002 to 2022. In addition to the keywords mentioned above, more terms on various aspects of BrS were unveiled. Heart disease (2002–2006), cellular basis (2004–2010), early repolarization (2011–2016), registry (2015–2018), and guideline (2018–2022) all have high strength (>5), implying that they were among the hot topics during the different stages of the BrS research.

Table 5.

Table 5

Top 25 keywords with the strongest citation bursts in BrS research (2002–2022).

4.2. Co-citation analysis

Co-citation analysis can identify patterns and trends regarding the structure and dynamics of the underlying scientific literature. A citation refers to the fact that article A refers to an existing article B. A is known as the citing article, and B is called the cited reference. Co-citations refer to the fact that 2 references are cited simultaneously by the third article. The collection of co-cited references is the foundation of a discipline, while the citing articles represent the research frontiers. Co-citation clustering is determined by the terms extracted from the citing articles, which can be regarded as the research frontiers. As depicted in Figure 6, there are 11 co-citation clusters, and the largest 3 clusters are: #0 expert consensus statement, #1 genetic testing, #2 sudden unexplained nocturnal death syndrome. Among the 41,303 co-cited references retrieved, Table 6 lists the 10 most frequently cited references, of which an expert consensus statement published in Circulation by Antzelevitch et al[26] in 2005 had the highest citations.

Figure 6.

Figure 6.

Timeline and cluster view of co-citation analysis in the field of BrS (2002–2022). BrS = Brugada syndrome.

Table 6.

The top 10 co-cited references concerning BrS (2002–2022).

No. Cited references Citation
1 Antzelevitch C, 2005, CIRCULATION, Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association 234
2 Priori SG, 2013, HEART RHYTHM, HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes 159
3 Priori SG, 2002, CIRCULATION, Natural history of Brugada syndrome: insights for risk stratification and management 152
4 Probst V, 2010, CIRCULATION, Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada Syndrome Registry 142
5 Priori SG, 2012, JACC, Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry 125
6 Wilde AAM, 2002, CIRCULATION, Proposed diagnostic criteria for the Brugada syndrome: consensus report 125
7 Brugada J, 2002, CIRCULATION, Long-Term Follow-Up of Individuals With the Electrocardiographic Pattern of Right Bundle-Branch Block and ST-Segment Elevation in Precordial Leads V1 to V3 123
8 Brugada R, 2000, CIRCULATION, Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts 121
9 Antzelevitch C, 2007, CIRCULATION, Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death 117
10 Haissaguerre M, 2008, NEJM, Sudden Cardiac Arrest Associated with Early Repolarization 116

BrS = Brugada syndrome.

Based on the statistical and visual analysis, we summarize the key documents and innovative findings that have advanced the discipline in chronological order and citation frequency. Publications from journals like Circulation, Journals of Molecular and Cellular Cardiology, New England Journal of Medicine, and Journals of the American College of Cardiology were mainly analyzed to ensure research quality. According to the research content, these highly-cited papers can be classified into 4 categories: pathophysiology, diagnosis, risk stratification, and management.

4.2.1. Genetics and pathophysiology.

As a heterogenous genetic disease, BrS is caused by mutations that influence the sodium current or other ionic currents. In 1998, Chen et al[8] identified the first pathogenic variant in association with BrS in the SCN5A gene (NaV1.5, BrS1). In a 2018 review by Wilde et al,[27] this gene encodes cardiac sodium channel Nav1.5, which is responsible for phase 0 of the cardiac action potential. SCN5A mutations, classified as BrS 1 type, result in loss of function of the sodium channel. In 2010, Kapplinger et al[28] performed a retrospective analysis of 2111 patients who were referred for BrS genetic testing and added 200 novel SCN5A mutations. Of note, they demonstrated that an identifiable SCN5A variant is found only in ~20% of BrS patients. Several pathogenic variants associated with BrS have been identified in other genes and altogether may be responsible for 2%~5% of diagnosed cases, according to a recent review by Brugada et al.[11] Some are responsible for other sodium channel, including SCN1B (NaVβ1, BrS5),[29] SCN2B (NaVβ2, BrS14),[30] SCN3B (NaVβ3, BrS7),[31] and SCN10A (NaV1.8, BrS17).[32] Some genes encode ion channels that carry calcium or potassium ions. The representative fundings include CACNA1C (Cav1.2, BrS3) and CACNB2b (Cavβ2b, BrS4) by Antzelevitch et al in 2007.[33] In 2008, Deplón et al[34] first described KCNE3 (MiRP2, BrS6) which regulates the potassium channel Ito associated with BrS. Others generate proteins that interact with ion channels, like GPD1-L (BrS2) reported by London in 2007. A GPD1-L mutation may decrease cardiac Na+ current and causes BrS.[35] Through a genome-wide association study, Bezzina et al[36] detected 3 alleles comprising SCN5A, SCN10A, and HEY2 (BrS18) which solitarily increased BrS risk, as well as additively.

The underlying mechanism of BrS remains a subject of debate. Currently, there are 2 leading hypotheses. In a scholarly debate, Wilde et al[37] addressed that depolarization disorder forms the basis of the BrS. The depolarization hypothesis relies on abnormally slow conduction in the right ventricle and cardiac structural changes. On the contrary, Antzelevitch et al argued the repolarization hypothesis as the predominant mechanism underlying BrS. The repolarization hypothesis relies on transmural dispersion of repolarization between the endocardium and epicardium of the right ventricle outflow tract. As BrS can be caused by mutations in various genes, different mechanisms may bear the responsibility for the arrhythmias seen in different patients.

4.2.2. Diagnosis.

Current In 2002, Wilde et al[38] proposed the first proper diagnostic criteria for BrS through ESC consensus documents. Adjusted guidelines were reported in 2005[26] and 2013[39] till Shangai criteria in 2016[40] and the last review was made by Brugada et al in 2018.[11] Until 2013, BrS diagnosis recommended both the presence of type 1 ECG pattern and clinical manifestations. However, because many individuals with type 1 ECG are asymptomatic, the 2013 consensus statement required no further evidence of malignant arrhythmias.[41] Previous guidelines did not invlove additional criteria for patients with drug-induced type 1 ECG, thereby possibly overdiagnosing BrS. Hence, the recent Shanghai citeria includes additional information to make a definite diagnosis.

4.2.3. Risk stratification.

After the diagnosis, the number one issue is mainly associated with the patient’s outcome and prognosis. Risk stratification in BrS patients, influenced by various clinical, ECG, and electrophysiological factors, aims to identify those with a greater likelihood of serious arrhythmic events. In 2002, Pedro and Josep Brugada first analyzed the long-term follow-up data of BrS patients (N = 334). They proposed that inducibility VAs and type 1 ECG are predictors of arrhythmia occurrence.[42] In the same year, Priori et al[43] failed to corroborate a utility for VAs inducibility at programmed electrical stimulation in their BrS cohort (N = 200). In contrast, they demonstrated that the presence of a spontaneous type 1 ECG combined with the history of cardiogenic syncope has the greatest impact on serious arrhythmic events; accordingly, they proposed a risk stratification scheme that recommends ICD only in patients with these manifestations. In 2010, this prospective evaluation was confirmed by Probst et al[44] in a long-term prognosis involving 1029 BrS patients from 4 European countries (FINGER registry). They also found that patient age and sex are not predictive of arrhythmic events. In 2012, the PRELUDE cohort (N = 208) identified 2 novel predictors of life-threatening events: the presence of QRS fragmentation and short ventricular refractory period.[45] Recent evidences showed that conduction abnormalities may also play a role in the risk stratification in Brugada patients. In 2019, Migliore et al[46] first demonstrated that first-degreee atrioventricular block is an independent predictor of life-threatening arrhythmic events, as well as a stronger marker of arrhythmic risk than a spontaneous ECG changes. According to their recent study, S-wave in lead I on basal ECG is the only independent predictor of persistent risk of malignant arrhythmic events.[47] Therefore, these easily obtainable ECG markers should be considered in designing clinical algorithm for individual risk assessment in BrS. Overall, the presence of spontaneously diagnostic BrS ECG, cardiogenic syncope, conduction abnormalities, along with consideration for undertaking programmed electrical stimulation have been identified as risk markers for future events.

4.2..4. Management.

The main aim when treating BrS patients is to reduce the risk of SCD due to malignant arrhythmias. In the 2013 HRS/EHRA/APHRS consensus statement, the first line of treatment, suitable for all BrS patients, is lifestyle changes.[39] These include avoiding substances that may increase the risk of serious arrhythmias, such as excessive alcohol and certain medications, and treating fever rapidly with antipyretics. Postema et al[48] provided a list of drugs that are contraindicated in BrS. An ICD should always be implanted in symptomatic patients for the prevention of VAs and SCD, according to the recommendations of the international consensus and guidelines.[41] In a cohort with 60 BrS patients, Belhassen et al[49] reported that quinidine, an antiarrhythmic drug, is useful in the pharmacologic management of BrS. Arrhythmic events occurred in only 2 cardiac arrest survivors treated with ICD alone but did not recur on quinidine. A further treatment option is a radiofrequency ablation. Pappone et al[49] demonstrated that arrhythmogenic electrophysiological substrate elimination by radiofrequency ablation results in ECG normalization and ventricular tachycardia/VF noninducibility, in 133/135 (98.5%) patients during a median follow-up of 10 months.

5. Emerging trends

We explore the emerging trends in the BrS field by analyzing burst keywords and references during the past 3 years (2019–2022). As shown in Table 7, some keywords are outcomes of BrS: “event,” “sudden cardiac arrest,” and “sudden cardiac death.” Some are novel pathologic concepts: “common variant,” “J wave syndrome,” and “cardiac channelopathy.” Others like “exercise” and “cardioverter defibrillator” involve management of BrS. These keywords might be the hotspots for current and future BrS research.

Table 7.

Table 7

The emerging burst keywords in the field of BrS (2019–2022).

For further analysis, we selected recent references with the strongest citation bursts (Table 8). Half of the papers focused on the pathophysiology associated with BrS, especially the structure and function of the cardiac sodium channel. Further investigation into this concept would enrich the understanding of the underlying pathophysiology of BrS and may give rise to future exploration of the targeted therapy. The other studies deal with SCD among youngsters and athletes. These findings highlight the need for complementary preventive strategies. Specifically, the 2013 HRS/EHRA/APHRS expert consensus statement by Priori et al appeared again on this list, which summarized the clinical guidelines for diagnosis, risk stratification, and management of BrS patients. This document has considerably improved the care of BrS patients. Based on the references above, we note that the pathophysiological basis of BrS is incompletely understood. However, the progress in the understanding of BrS has been steady, and the future of BrS patients looks very promising. In summary, the underlying pathophysiological mechanisms (especially the ion channel abnormality and related genetic basis), the development of novel therapies, and personalized risk assessment for different populations might be the emerging trends of BrS research.

Table 8.

Table 8

Top 10 references with the strongest citation bursts concerning BrS (2019–2022).

6. Discussion

In this study, we conducted a bibliometric analysis to explore the research hotspots and developmental trends of BrS. Firstly, general information (i.e., the annual publications, authors, institutions, countries, and journals) was quantitatively analyzed. BrS is a progressively developing research field with an increase in publications over time, due to the enhanced recognition of this entity. The top 10 institutions and authors were concentrated in the USA and European countries, indicating their outstanding contributions to BrS advancement. Second, we obtained the research hotspots in BrS by analyzing the keywords and citations. Notably, we focused our analysis on highly cited publications from influential journals and identified the dynamic evolutions of research hotspots in the pathophysiology, diagnosis, risk stratification, and management of BrS. Finally, we highlighted several emerging trends by visualizing BrS-themed publications and keywords during the past 3 years. However, there were some limitations in our study. Firstly, the database is updated continuously and dynamically. Hence, our results are essentially temporary and by default will not incorporate ongoing and future research areas. Secondly, only English publications from Science Citation Index-expanded databases were included. Therefore, a discrepancy may exist between our analysis and the real publication characteristics.

Overall, BrS remains a challenging disease entity. Its underlying pathophysiological mechanisms remain to be elucidated. Perhaps the polygenic factors are important for both the phenotypic expression of BrS and clinical outcomes. These variables lead to the present uncertainty and difficulty in making the correct diagnosis, risk stratification, and management. Hence then, physicians should assess patients with definite or possible BrS to implement personalized therapies, with the help of current BrS guidelines.

7. Conclusion

This bibliometric analysis reveals that the BrS research is prosperous during the past 20 years. The USA, Japan, and some European countries like the Netherlands had made many outstanding breakthroughs in this field. The vast majority of articles concerning BrS were published and cited in influential scientific journals. Among them, Circulation, Journals of the American College of Cardiology, and Heart Rhythm were the 3 most representative journals. The research hotspots over the decades were pathophysiology, diagnosis, risk stratification, and management. Our results indicate that the underlying mechanisms, novel therapies, and personalized risk assessment might be the future trends of the BrS research.

Author contributions

Conceptualization: Shixu Liu, Hengyuan Liu.

Data curation: Shixu Liu, Hongsheng Xia, Yanyi Liu, Xiao Xia, Xiaohong Liu.

Formal analysis: Shixu Liu, Hongsheng Xia, Xiaoyan Yao.

Funding acquisition: Guangxi Li.

Investigation: Shixu Liu.

Methodology: Shixu Liu, Xiaoyan Yao, Xiao Xia, Dandan Wang.

Resources: Shixu Liu, Xiaoyan Yao.

Software: Shixu Liu.

Validation: Shixu Liu, Yanyi Liu.

Visualization: Shixu Liu.

Writing – original draft: Shixu Liu.

Writing – review & editing: Guangxi Li.

Abbreviations:

BC
betweenness centrality
BrS
Brugada syndrome
ECG
electrocardiogram
ICD
implantable cardioverter defibrillator
Nc
citations without self-citations
Np
number of publications
SCD
sudden cardiac death
VA
ventricular arrhythmia
VF
ventricular fibrillation

SL, HX, XY, and HL contributed equally to this work.

This work was supported by the National Natural Science Foundation of China (grant no. 82074262).

This bibliometric analysis based on published data. Therefore, ethics approval is not necessary.

The authors have no conflicts of interest to disclose.

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

How to cite this article: Liu S, Xia H, Yao X, Liu H, Liu Y, Xia X, Wang D, Liu X, Li G. Frontier and hotspot evolution in Brugada syndrome: A bibliometric analysis from 2002 to 2022. Medicine 2023;102:7(e33038).

Contributor Information

Shixu Liu, Email: 331682314@qq.com.

Hongsheng Xia, Email: 719231832@qq.com.

Xiaoyan Yao, Email: yxy875747@163.com.

Hengyuan Liu, Email: 331682314@qq.com.

Yanyi Liu, Email: 331682314@qq.com.

Xiao Xia, Email: 719231832@qq.com.

Dandan Wang, Email: wdd19940416@163.com.

Xiaohong Liu, Email: 331682314@qq.com.

References

  • [1].Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol. 1992;20:1391–6. [DOI] [PubMed] [Google Scholar]
  • [2].Yan G-X, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation. 1996;93:372–9. [DOI] [PubMed] [Google Scholar]
  • [3].Miyazaki T, Mitamura H, Miyoshi S, et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol. 1996;27:1061–70. [DOI] [PubMed] [Google Scholar]
  • [4].Nademanee K, Veerakul G, Nimmannit S, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation. 1997;96:2595–600. [DOI] [PubMed] [Google Scholar]
  • [5].Coppola G, Corrado E, Curnis A, et al. Update on Brugada syndrome 2019. Curr Probl Cardiol. 2021;46:100454. [DOI] [PubMed] [Google Scholar]
  • [6].Antzelevitch C, Patocskai B. Brugada syndrome: clinical, genetic, molecular, cellular, and ionic aspects. Curr Probl Cardiol. 2016;41:7–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Sarquella-Brugada G, Campuzano O, Arbelo E, et al. Brugada syndrome: clinical and genetic findings. Genet Med. 2016;18:3–12. [DOI] [PubMed] [Google Scholar]
  • [8].Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998;392:293–6. [DOI] [PubMed] [Google Scholar]
  • [9].Krahn AD, Behr ER, Hamilton R, et al. Brugada syndrome. Clin Electrophysiol. 2022;8:386–405. [DOI] [PubMed] [Google Scholar]
  • [10].de Luna AB, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol. 2012;45:433–42. [DOI] [PubMed] [Google Scholar]
  • [11].Brugada J, Campuzano O, Arbelo E, et al. Present status of Brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1046–59. [DOI] [PubMed] [Google Scholar]
  • [12].Gu D, Li J, Li X, et al. Visualizing the knowledge structure and evolution of big data research in healthcare informatics. Int J Med Inform. 2017;98:22–32. [DOI] [PubMed] [Google Scholar]
  • [13].Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57:359–77. [Google Scholar]
  • [14].Van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [15].Ma D, Yang B, Guan B, et al. A bibliometric analysis of pyroptosis from 2001 to 2021. Front Immunol. 2021;12:731933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Cooper ID. Bibliometrics basics. J Med Libr Assoc. 2015;103:217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Liu S, Xia K, Liu X, et al. Bibliometric analysis of Birt-Hogg-Dubé syndrome from 2001 to 2021. Front Med (Lausanne). 2022;9:857127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Liu S, Cui X, Xia K, et al. A bibliometric analysis of pulmonary alveolar proteinosis from 2001 to 2021. Front Med (Lausanne). 2022;9:846480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Hirsch JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci USA. 2005;102:16569–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Jones T, Huggett S, Kamalski J. Finding a way through the scientific literature: indexes and measures. World Neurosurg. 2011;76:36–8. [DOI] [PubMed] [Google Scholar]
  • [21].Roldan-Valadez E, Salazar-Ruiz SY, Ibarra-Contreras R, et al. Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics. Ir J Med Sci. 2019;188:939–51. [DOI] [PubMed] [Google Scholar]
  • [22].Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. 2004;101:5303–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annual Symposium Proceedings, American Medical Informatics Association, 2005, pp. 724. [PMC free article] [PubMed] [Google Scholar]
  • [24].Chen C, Hu Z, Liu S, et al. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12:593–608. [DOI] [PubMed] [Google Scholar]
  • [25].McCain KW. Mapping authors in intellectual space: population genetics in the 1980s. Commun Res. 1989;16:667–81. [Google Scholar]
  • [26].Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659–70. [DOI] [PubMed] [Google Scholar]
  • [27].Wilde AAM, Amin AS. Clinical spectrum of SCN5A mutations: long QT syndrome, Brugada syndrome, and cardiomyopathy. JACC Clin Electrophysiol. 2018;4:569–79. [DOI] [PubMed] [Google Scholar]
  • [28].Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7:33–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Watanabe H, Koopmann TT, Le Scouarnec S, et al. Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Riuró H, Beltran-Alvarez P, Tarradas A, et al. A Missense mutation in the sodium channel β2 subunit reveals SCN2B as a new candidate gene for Brugada syndrome. Hum Mutat. 2013;34:961–6. [DOI] [PubMed] [Google Scholar]
  • [31].Hu D, Barajas-Martinez H, Burashnikov E, et al. A mutation in the β3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circulation. 2009;2:270–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Hu D, Barajas-Martínez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol. 2014;64:66–79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115:442–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Delpón E, Cordeiro JM, Núñez LA, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circulation. 2008;1:209–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].London B, Michalec M, Mehdi H, et al. Mutation in glycerol-3-phosphate dehydrogenase 1–like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation. 2007;116:2260–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet. 2013;45:1044–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Wilde AA, Postema PG, Di Diego JM, et al. The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol. 2010;49:543–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Wilde AA, Antzelevitch C, Borggrefe M, et al.; Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation. 2002;106:2514–9. [DOI] [PubMed] [Google Scholar]
  • [39].Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63. [DOI] [PubMed] [Google Scholar]
  • [40].Antzelevitch C, Yan GX, Ackerman MJ, et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Heart Rhythm. 2016;13:e295–324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36:2793–867. [DOI] [PubMed] [Google Scholar]
  • [42].Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation. 2002;105:73–8. [DOI] [PubMed] [Google Scholar]
  • [43].Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–7. [DOI] [PubMed] [Google Scholar]
  • [44].Probst V, Veltmann C, Eckardt L, et al. Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry. Circulation. 2010;121:635–43. [DOI] [PubMed] [Google Scholar]
  • [45].Priori SG, Gasparini M, Napolitano C, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012;59:37–45. [DOI] [PubMed] [Google Scholar]
  • [46].Migliore F, Testolina M, Zorzi A, et al. First-degree atrioventricular block on basal electrocardiogram predicts future arrhythmic events in patients with Brugada syndrome: a long-term follow-up study from the Veneto region of Northeastern Italy. Europace. 2019;21:322–31. [DOI] [PubMed] [Google Scholar]
  • [47].Migliore F, Martini N, Calo L, et al. Predictors of late arrhythmic events after generator replacement in Brugada syndrome treated with prophylactic ICD. Front Cardiovasc Med. 2022;9:964694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335–41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Pappone C, Brugada J, Vicedomini G, et al. Electrical substrate elimination in 135 consecutive patients with Brugada syndrome. Circ Arrhythm Electrophysiol. 2017;10:e005053. [DOI] [PubMed] [Google Scholar]

Articles from Medicine are provided here courtesy of Wolters Kluwer Health

RESOURCES